

Attorney Docket No.: PB607284USw

Amendments To The Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A method of treating a human or animal subject suffering from a condition which is mediated by the activity of CB2 receptors or a condition which is mediated by PDE4 which comprises administering to said subject a therapeutically effective combination of one or more CB2 modulators and one or more PDE4 inhibitors.

2. – 3. (Canceled)

4. (Currently Amended) The method according to claim 1 ~~or the use according to claim 2 or claim 3~~, in which the CB2 modulator is selected from a compound of formula (I):



wherein

Y is phenyl, optionally substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl and halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;


R³ is an optionally substituted 4- to 8- membered non-aromatic heterocyclyl group, an optionally substituted C₃₋₈ cycloalkyl group, an

Attorney Docket No.: PB607284USw

optionally substituted straight or branched C₁₋₁₀ alkyl, a C₅₋₇ cycloalkenyl or R⁵;

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

R⁵ is



wherein p is 0, 1 or 2 and X is CH₂, O, S, SO or SO₂;

R⁶ is methyl, chloro or CHxF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SOqR⁹;


R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

R⁹ is C₁₋₆alkyl; and

q is 0, 1 or 2;

or a compound of formula (II):



wherein


Y is phenyl, substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and halosubstituted C₁₋₆ alkyl;

R² is C(R⁷)₂R³;

R³ is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A:

Attorney Docket No.: PB607284USw



(A)

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, and halosubstituted C_{1-6} alkyl, $COCH_3$, or SO_2Me ;

R^6 is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

R_a can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b can be independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$ or $NHCOOC_{1-6}alkyl$; and

R^7 can be independently hydrogen or C_{1-6} alkyl, with the proviso that the compound is not


2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide;

2-(4-*tert*-butyl-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzyl-methyl-amide;

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-methoxy-benzylamide; or

2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid 2-bromo-benzylamide;

or a compound of formula (III):



(III)

Attorney Docket No.: PB607284USw


wherein

Y is phenyl, substituted with one, two or three substituents;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstituted C_{1-6} alkyl;

 R^2 is $(CH_2)_m R^3$;

R^3 is an unsubstituted or substituted 5- to 6- membered aromatic heterocyclyl group, or group A:



(A)


R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstituted C_{1-6} alkyl, $COCH_3$, and SO_2Me ;

R^6 is unsubstituted or substituted (C_{1-6}) alkyl or chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6}) alkyl or chloro and R^6 is hydrogen;

Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb can independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo substituted C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$, SO_2CH_3 , $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$; and m is 1 or 2;

or a compound of formula (IV):



(IV)

wherein

Attorney Docket No.: PB607284USw

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstituted C_{1-6} alkyl;


R^2 is $(CH_2)_m R^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R^3 is a 4- to 8- membered non-aromatic heterocyclyl group, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{2-10} alkenyl, a C_{3-8} cycloalkenyl, a C_{2-10} alkynyl, or a C_{3-8} cycloalkynyl any of which can be unsubstituted or substituted or R^5 ;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstituted C_{1-6} alkyl, $COCH_3$, or SO_2Me ;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2 , O, or S;

R^6 is a substituted or unsubstituted (C_{1-6}) alkyl or chloro and R^{10} is hydrogen or R^{10} is a substituted or unsubstituted (C_{1-6}) alkyl or chloro and R^6 is hydrogen;

R^7 is OH, C_{1-6} alkoxy, $NR^{8a}R^{8b}$, $NHCO R^9$, $NHSO_2R^9$ or SO_qR^9 ;

R^{8a} is H or C_{1-6} alkyl;

R^{8b} is H or C_{1-6} alkyl;

R^9 is C_{1-6} alkyl; and

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

5. (Currently Amended) A method according to claim 1 ~~or the use according to claim 2 or claim 3~~ in which the PDE4 inhibitor is selected from cilomilast, AWD-12-281, NCS-613, D-4418, CI-1018, V-11294A, roflumilast or T-4401, and pharmaceutically acceptable derivatives thereof.

Attorney Docket No.: PB607284USw

6. (Currently Amended) The method of claim 1 ~~or the use of claim 2 or claim 3~~ wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis, osteoporosis, lung disorders, for example asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD) and cough, or a disorder which can be treated with a bronchodilator.

7. (Original) A pharmaceutical composition comprising one or more CB2 modulators and one or more PDE4 inhibitors adapted for use in human or veterinary medicine.